Karyopharm Delays Third-Quarter Report Amid Bankruptcy Proceedings

• Karyopharm Therapeutics cannot file its September 30, 2026, quarterly report by the deadline or within the permitted five-day extension.
• Chapter 11 proceedings begun November 2, 2026, have diverted management resources; limited finance and accounting staffing also contributed to the delay.
• No filing date has been estimated as quarterly closing procedures and technical accounting assessments remain incomplete.
• Results for the three and nine months are expected to differ significantly from 2025, primarily reflecting bankruptcy preparation and strategic transaction costs.
• The proposed reorganization plan would cancel existing equity without distributions; the Ayrmid merger is expected to close in the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-460615), on November 13, 2026, and is solely responsible for the information contained therein.